OCUP Company Profile and Key Details

OCUP has shown mixed momentum, gaining 4.72% over the past week and -34.8% over the past quarter, though year-to-date performance is down -55.81%. Short-term trend indicators are bullishly aligned (SMA20 -8.52%, SMA50 -8.96%, SMA200 -36.46%). The stock’s 14-day RSI is 37.61 (weak momentum), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -65.58% below its high and over 1.74% above its low.

Ocuphire Pharma, Inc. generated EPS of -$0.55 over the past year. Five-year average earnings growth is 53.36%. The latest quarter delivered EPS of $0.25. The next quarter is forecast at -$0.25. Next year's EPS is expected at $24.51. Ocuphire Pharma, Inc. earnings surprise history is a mixed track record. The quarter that ended November 11, 2024, missed forecasts by -200.0%. The prior quarter beat by 3.45%. Over the last six quarters, Apple has recorded several small beats. These include -213.64% in November 13, 2023.

Ocuphire Pharma, Inc. has 26.20 million shares outstanding. The public float is 24.52 million shares, elevated short interest at 3.74% of float. This equals 930.64 thousand shares. The short ratio is 10.1 days. Ahn Chang Ho holds 6.01 million shares, Park Young Soon has 2.74 million shares and Jeong Tae Heum has 505.00 thousand shares.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Ocuphire Pharma, Inc. (NASDAQ:OCUP) closed at $1.17 USD, losing -$0.16 (-12.03%) from the previous close of $1.33. The stock is currently mid-range between its 52-week high and low $1.07 and $3.40. With a market capitalization of about $31.74 million, Ocuphire Pharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.31). Key stats such as the average daily volume over the past year has been around 139.15 thousand shares, trading with heavier-than-usual volume. Headquartered in Farmington Hills, MI, Ocuphire Pharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO George Magrath, the company employs approximately 14 people and listed since November 10, 2005. Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

Our AI price prediction model suggests that Ocuphire Pharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.31%, with price expected at $0.83 by December 04, 2024, within a range of $0.78 to $0.88 3-Month Outlook: Projected fall of -58.16%, reaching $0.41 by January 30, 2025, with a range of $0.16 to $0.44. 1-Year Outlook: Projected gain of 44.9%, with price at $1.42 by November 04, 2025, within a range of $0.00 to $0.00.

Ocuphire Pharma, Inc. (NASDAQ:OCUP) shares are down -55.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Ocuphire Pharma, Inc. trading at a premium to the broader market with a P/E of -14.68. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.00, suggesting 1838.78% upside. Our AI forecast model points to short-term weakness (-15.31% over two weeks), a medium-term fall (-58.16% over three months), and a longer-term gain (44.9% over one year), with expected trading ranges indicating moderate volatility.

Ocuphire Pharma, Inc. trades at a P/E ratio of -14.68, slightly below the S&P 500 average, with a price-to-sales ratio of 7.26 and a price-to-book ratio of 47.43 reflecting a rich premium to book value. The P/FCF stands at -0.9, also below market averages. Compared to sector medians, Ocuphire Pharma, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.